OBJECTIVE: To conduct a thorough QT study of levocetirizine, a non-sedating antihistamine, in accordance with International Conference on Harmonisation (ICH) E14 guidance. METHODS: The study was designed as a single-dose, placebo and positive-controlled, four-way crossover, randomised trial in which 52 healthy male and female subjects participated. Levocetirizine (5 and 30 mg) and placebo were administered double-blind, and the positive control, moxifloxacin (400 mg), was open-label. Electrocardiograms (ECGs) were obtained by continuous Holter monitoring at various time points (three per time point) during a 24-h period at baseline and after each treatment. The ECGs were read centrally in a blinded manner. QT intervals were corrected for heart rate using a gender- and study-specific correction (QTcSS) and Fridericia's correction (QTcF). The largest QTc time-matched and baseline-subtracted difference between each active drug and the placebo (largest delta delta QTcSS) was derived from a mixed-effect analysis of variance. RESULTS: The one-sided 95% upper limits of the largest delta delta QTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively. Similar results were obtained for the delta delta QTcF data. Statistically, moxifloxacin significantly lengthened the QTcSS, with a one-sided 95% lower limit of the largest delta delta QTcSS of 10.5 ms and a mean estimate of 13.4 ms. There was no relationship between the measured delta QTcSS and the plasma concentration of levocetirizine, whereas a statistically significant linear relationship was observed with the plasma concentration of moxifloxacin [slope estimate 0.004 ms/(ng/mL); 95% confidence interval: 0.003-0.005]. CONCLUSIONS: Overall, the results of this thorough QT study indicate that the methodology of the trial was valid and sensitive enough to demonstrate the absence of effect of levocetirizine at both therapeutic (5 mg) and supra-therapeutic (30 mg) doses on cardiac repolarisation.
RCT Entities:
OBJECTIVE: To conduct a thorough QT study of levocetirizine, a non-sedating antihistamine, in accordance with International Conference on Harmonisation (ICH) E14 guidance. METHODS: The study was designed as a single-dose, placebo and positive-controlled, four-way crossover, randomised trial in which 52 healthy male and female subjects participated. Levocetirizine (5 and 30 mg) and placebo were administered double-blind, and the positive control, moxifloxacin (400 mg), was open-label. Electrocardiograms (ECGs) were obtained by continuous Holter monitoring at various time points (three per time point) during a 24-h period at baseline and after each treatment. The ECGs were read centrally in a blinded manner. QT intervals were corrected for heart rate using a gender- and study-specific correction (QTcSS) and Fridericia's correction (QTcF). The largest QTc time-matched and baseline-subtracted difference between each active drug and the placebo (largest delta delta QTcSS) was derived from a mixed-effect analysis of variance. RESULTS: The one-sided 95% upper limits of the largest delta delta QTcSS for levocetirizine were 5.7 ms (5 mg) and 3.9 ms (30 mg), with mean estimates of 2.9 and 1.1 ms, respectively. Similar results were obtained for the delta delta QTcF data. Statistically, moxifloxacin significantly lengthened the QTcSS, with a one-sided 95% lower limit of the largest delta delta QTcSS of 10.5 ms and a mean estimate of 13.4 ms. There was no relationship between the measured delta QTcSS and the plasma concentration of levocetirizine, whereas a statistically significant linear relationship was observed with the plasma concentration of moxifloxacin [slope estimate 0.004 ms/(ng/mL); 95% confidence interval: 0.003-0.005]. CONCLUSIONS: Overall, the results of this thorough QT study indicate that the methodology of the trial was valid and sensitive enough to demonstrate the absence of effect of levocetirizine at both therapeutic (5 mg) and supra-therapeutic (30 mg) doses on cardiac repolarisation.
Authors: Gary J Noel; Jaya Natarajan; Shuchean Chien; Thomas L Hunt; Daniel B Goodman; Robert Abels Journal: Clin Pharmacol Ther Date: 2003-04 Impact factor: 6.875
Authors: Gregory C Williams; Katherine M Dunnington; Ming-Yi Hu; Thomas R Zimmerman; Zhiming Wang; Kerry B Hafner; Maxine Stoltz; Edward K Hill; Jean T Barbey Journal: J Cardiovasc Electrophysiol Date: 2006-04
Authors: J T Sullivan; M Woodruff; J Lettieri; V Agarwal; G J Krol; P T Leese; S Watson; A H Heller Journal: Antimicrob Agents Chemother Date: 1999-11 Impact factor: 5.191
Authors: Borje Darpo; Nenad Sarapa; Christine Garnett; Charles Benson; Corina Dota; Georg Ferber; Venkateswar Jarugula; Lars Johannesen; James Keirns; Kevin Krudys; Catherine Ortemann-Renon; Steve Riley; Danise Rogers-Subramaniam; Norman Stockbridge Journal: Ann Noninvasive Electrocardiol Date: 2013-12-30 Impact factor: 1.468
Authors: Jonathan Vigne; Joachim Alexandre; Fabienne Fobe; Paul Milliez; Magalie Loilier; Sophie Fedrizzi; Antoine Coquerel Journal: Eur J Clin Pharmacol Date: 2015-01-28 Impact factor: 2.953
Authors: Ester Donado; Iñaki Izquierdo; Iñaki Pérez; Olga García; Rosa M Antonijoan; Ignaci Gich; Anna Solans; Juana Peña; Joel Morganroth; Manuel J Barbanoj Journal: Br J Clin Pharmacol Date: 2010-04 Impact factor: 4.335